Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers